Buy Aurobindo Pharma; target of Rs 915: Sharekhan

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Sharekhan's research report on Aurobindo Pharma

Aurobindo Pharma (Aurobindo) reported a weak performance for Q1FY22 and the results missed estimates. Multiple headwinds like higher price erosion and inventory built up across channels have emerged for the US business and the same is expected to sustain at-least in the near term. Over the long term, efforts to build presence in specialty segments - biosimilars, oncology & injectables could be the growth drivers, but near term headwinds in US business are expected to slow down the growth. .

Outlook

At CMP, the stock is trading P/E of 12.4x and 10.8x its FY22E and FY23E EPS, which is attractive. we retain our Buy recommendation with revised PT of Rs. 915

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More